Member Info for nomlungu

The US data is likely to disappoint. How will Trump react after his 'Salute To America' 4th of July parade?

A tweet-storm or more tariffs?

bleak day - apologies

I can only hope we never have such a leak day...

https://www.nytimes.com/2019/07/03/nyregion/luis-alvarez-funeral.html

Kenny,

$3.81? TRX is trading at pennies and Woodford has not declared any sells of his stake, and they are contractually required to raise $5m as part of a recently announced financing agreement.

I am only looking to trade a bounce... and there is life in this cat. I am only targeting a £5k profit though.

https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/TRX/14097059.html

I have recently put money into the Pictet Security fund - Trump is likely to allow the Chinese to 'ship' Iranian oil against the Sinopec debt. I think that the US geopolitic thoughts are that they want to get the Chinese Navy to protect oil shipments in the Strait of Hormuz.

https://www.reuters.com/article/us-mideast-iran-usa/iran-to-boost-uranium-enrichment-level-breaching-nuclear-pact-rouhani-idUSKCN1TY18E

https://www.politico.com/story/2019/07/03/trump-china-iran-oil-1396052

I am uneasy about profiting from conflicts but if the returns are greater than inflation and the stupid returns on cash I will reluctantly participate when a few percent can be picked up weekly.

Unfortunately it took me until in my late forties despite me working sporadically.

And Abcam sell some of the proteins kits required (which has given me a 40% rise over the last 4 months).

https://www.abcam.com/products?keywords=fbs

This came to my attention:

https://www.nature.com/articles/s41467-018-07579-y#Sec9

I have an interest in extracellular matrices - it is part of the science behind Tissue Regenix which I am currently looking for a bottom feeding bargain. The hair loss market in the US is expected to be worth over $10 billion a year within the next couple of years.

The science is complicated and my knowledge, whilst better than a lyman's, is not at PHD level. But I can smell money and bricks of bank notes can smell surprisingly sweet.

ValJu,

I am retired so am likely have a different approach to investing than you - I only look for short term profit on speculative investments in companies that do not generate positive cash flow and pay out dividends.

If Valirx comes 'good' I might miss out on the rise; in the interim I do not see my stake being being diluted whilst having no 'skin in the game'. Each to their own, as they say.

Valirx was not on my radar when it went to 79p; I was invested when it went to 7p and sold out on the rise at 2.5p and 6.1p.

As I have said before, there are many big cancer companies who are looking for patent variations to extend the life of patents that will be expiring in the near future. If they can find some way of using Valirx's compounds to extend their patents they could be tempted just to keep their cash cows going. The ongoing decline in the value of the £ whilst the Brexit uncertainty (and possible hard Brexit) continues which could make Valirx's compounds more attractive to big bio but, as the share price shows, there has been little solid news of any deal that will be of short term financial benefit to Valirx.

Like most who follow the ups and downs of this share I would like to see the science behind the share prove beneficial to humanity and that shareholders benefit. But, and it is a BIG but, the financing model that they use does not meet the rules I adhere to for making a long term investment.

'ONE BIG placeing '?

The latest annual accounts show on page 49 net cash outflow from operating activities of £3,353,509 and £2,351,433 in 2018 and 2017 respectively. The current market capitalisation is a little over £1.5m.

To fund 2 years at the current cash burn would require about £6m - who would participate in putting £6m into a company valued at £1.5m? Even January now seems to suffer from delusional thoughts (or maybe he is just winding people up).

11 deleted posts - they seem to go missing like shareholder value.

Looks like EHGO have started dumping their stock (2 2.5m sells) - I wonder how long the artificial Bid of 0.17p will keep being displayed.

The figures might be bad - Bloomberg predicted recession over the weekend.

https://www.bloomberg.com/view/articles/2019-07-01/jobs-growth-suggest-the-u-s-may-already-be-in-recession

BB - I was unable to sell that share on Monday morning at the top of the market even though it had a momentary 10 percent spike. I was still able to sell my shares at 50p and since then the price has dropped to 43p.

The murky depths of AIM.

Some paperwork filed today looking for Trump's tax returns - depending on your browser settings you might be able to read the complaint from the Ways and Means committee.

https://www.axios.com/trump-tax-returns-house-democrats-sue-ce0cdc46-beed-4303-9755-671b760167db.html

I thought that 'the real donald' would have cut the funding off by now - I was surprised to receive an email today from [redacted] about the anti-ac4C antibody which included links to:

https://blast.ncbi.nlm.nih.gov/Blast.cgi

https://www.expasy.org

Make of it as you will.

No - I do not chew khat.

I posed a question about Antofagasta over the weekend - I note that the share price is down nearly 3% today on over ten thousand trades.

I will masticate on the trades...

As the excess Orange harvest hits the market I am going to service and reuse my juicer - a twin auger but only with a 1hp motor. It has been a while since I had home cold pressed juice in my morning smoothies.

The RNS states 'very pleased'.

I have faith in Jacques Vaillancourt - the investment is unlikely to have been made unless the Lagoa Salgada drilling campaign was progressing as expected. I posted this on the 7th of April:

'The 1st of April RNS of $5.2M drilling programme is the first step towards Ascendant increasing its ownership to 50% of Lagoa Salgada by investing US$9.0 million within 48 months and paying TH Crestgate US$3.5 million (per 2/8/18 RNS). If TH Crestgate end up receiving the $3.5m (£2.7m at current exchange rates) it would be a significant receipt for an AIM minnow with a current market capitalisation of £3.24m.'

Unfortunately, jobs data from the US is pointing to a recession in the US which as all know dampens global demand for commodities. Nonetheless, the RNS made me smile. As the £ devalues with the Brexit uncertainty the prospect of a significant $ receipt becomes more attractive.